Select Page

Our History

 

OncoSil Medical Ltd is a publicly traded medical device company (ASX: OSL) with a global footprint.

OncoSil™ is our brachytherapy device, which delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy.

Led by CEO and Managing Director Nigel Lange, OncoSil Medical operates in a number of markets across Europe and Asia Pacific and is headquartered in Sydney, Australia.

It has taken many committed individuals 15 years of dedication to get us to where
we are today.

2021 December

The PanCO Study is published in ESMO Open1

2020 November

OncoSil™ System receives regulatory approval in Switzerland.

2020 April

OncoSil™ system receives regulatory approval from Malaysia’s Medical Device Authority. Registered under Act 737. Registration Number: GD2812320-46044.

2020 May

OncoSil™ System receives regulatory approval from Singapore’s Health Sciences Agency

2020 April

British Standards Institute (BSI) grants European CE marking for the OncoSil™ System and designates OncoSil™ a breakthrough device for the treatment of locally advanced pancreatic cancer in combination with chemotherapy2

2020 March

FDA grants Breakthrough Device Designation for the OncoSil™ device for treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.

2018 June

The Microparticles are suspended in a specially formulated
Diluent for implantation

2018 March

First US study participant implanted with the OncoSil™ device as part of the OncoPaC-1 study3

2017 April

First study participant implanted with the OncoSil™ device as part of the global PanCO study1

2016 October

OncoSil Medical receives investigational device exemption (IDE) approval from the FDA to conduct a clinical study

2013

Enigma Therapeutics Ltd is acquired by Neurodiscovery Ltd Neurodiscovery Ltd changes its name to OncoSil Medical Ltd and focuses on the development of OncoSil™

2012

pSivida Corp grants an exclusive worldwide royalty-bearing license agreement with Enigma Therapeutics Ltd for the development of BrachySil™

2004 to 2009

Early clinical development phases for the OncoSil™ technology

2004

The OncoSil™ technology is developed as BrachySil™ by pSivida Corp

Reference:
  1. Ross PJ, Wasan HS, Croagh D et al. Results of a Single-Arm Pilot Study of 32P Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma with Gemcitabine/Nab-Paclitaxel or FOLFIRINOX Chemotherapy. ESMO Open February 2022; 7 (1): 100356.
  2. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
  3. OncoPaC-1 ClinicalTrials.gov Identifier: NCT03076216